209 related articles for article (PubMed ID: 22825030)
1. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
Fiskus W; Hembruff SL; Rao R; Sharma P; Balusu R; Venkannagari S; Smith JE; Peth K; Peiper SC; Bhalla KN
Breast Cancer Res Treat; 2012 Sep; 135(2):433-44. PubMed ID: 22825030
[TBL] [Abstract][Full Text] [Related]
2. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.
Fiskus W; Wang Y; Joshi R; Rao R; Yang Y; Chen J; Kolhe R; Balusu R; Eaton K; Lee P; Ustun C; Jillella A; Buser CA; Peiper S; Bhalla K
Clin Cancer Res; 2008 Oct; 14(19):6106-15. PubMed ID: 18829489
[TBL] [Abstract][Full Text] [Related]
3. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Dai Y; Chen S; Venditti CA; Pei XY; Nguyen TK; Dent P; Grant S
Blood; 2008 Aug; 112(3):793-804. PubMed ID: 18505786
[TBL] [Abstract][Full Text] [Related]
5. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
6. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.
Romanelli A; Clark A; Assayag F; Chateau-Joubert S; Poupon MF; Servely JL; Fontaine JJ; Liu X; Spooner E; Goodstal S; de Cremoux P; Bièche I; Decaudin D; Marangoni E
Mol Cancer Ther; 2012 Dec; 11(12):2693-703. PubMed ID: 23012245
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
Diamond JR; Eckhardt SG; Tan AC; Newton TP; Selby HM; Brunkow KL; Kachaeva MI; Varella-Garcia M; Pitts TM; Bray MR; Fletcher GC; Tentler JJ
Clin Cancer Res; 2013 Jan; 19(1):291-303. PubMed ID: 23136197
[TBL] [Abstract][Full Text] [Related]
11. Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.
Zhang XH; Rao M; Loprieato JA; Hong JA; Zhao M; Chen GZ; Humphries AE; Nguyen DM; Trepel JB; Yu X; Schrump DS
Cancer Biol Ther; 2008 Sep; 7(9):1388-97. PubMed ID: 18708766
[TBL] [Abstract][Full Text] [Related]
12. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
13. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
14. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
15. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Muscal JA; Scorsone KA; Zhang L; Ecsedy JA; Berg SL
Invest New Drugs; 2013 Feb; 31(1):39-45. PubMed ID: 22669335
[TBL] [Abstract][Full Text] [Related]
16. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
17. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Ann Hematol; 2010 Nov; 89(11):1081-7. PubMed ID: 20563869
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
Kai K; Kondo K; Wang X; Xie X; Pitner MK; Reyes ME; Torres-Adorno AM; Masuda H; Hortobagyi GN; Bartholomeusz C; Saya H; Tripathy D; Sen S; Ueno NT
Mol Cancer Ther; 2015 Dec; 14(12):2687-99. PubMed ID: 26443806
[TBL] [Abstract][Full Text] [Related]
20. Co-inhibition of Aurora A and Haspin kinases enhances survivin blockage and p53 induction for mitotic catastrophe and apoptosis in human colorectal cancer.
Lin CI; Chen ZC; Chen CH; Chang YH; Lee TC; Tang TT; Yu TW; Yang CM; Tsai MC; Huang CC; Yang TW; Lin CC; Wang RH; Chiou GY; Jong YJ; Chao JI
Biochem Pharmacol; 2022 Dec; 206():115289. PubMed ID: 36241092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]